An observational study in Children Born to Mothers Enrolled in the TOCOPROM Trial, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 6 Years to 78 Months. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, 2 of them phase 3. Premature Birth · Assistance Publique - Hôpitaux de Paris.
Among the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2025, is one of 6 observational ones, and was the 25th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →6 of the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 0 days–28 mo
By country, each count listing its studies:
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 6 Years to 78 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 480 is above the median of 120 across 809 observational studies indexed under Premature Birth.
Median enrollment 133 across the 20 interventional studies, 253 across the 6 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Premature Birth by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03976063Phase 3Assistance Publique - Hôpitaux de ParisTocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation | 2026-11 |
| NCT05586334Assistance Publique - Hôpitaux de ParisDevelopment and Clinical Evaluation of an Innovative Medical Device to Predict Preterm Birth (PrediMAP) | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the neurodevelopment at age 6 of children born to women with preterm prelabor rupture of membranes at 22 to 33 weeks of gestation, after antenatal exposure to nifedipine vs placebo.
Preterm prelabor rupture of membranes (PPROM) complicates 3% of pregnancies and accounts for one-third of preterm births. It is a leading cause of neonatal mortality and morbidity and increases the risk of maternal infectious morbidity. In cases of early PPROM (22 to 33 completed weeks' gestation), expectant management is recommended in the absence of labor, chorioamnionitis or fetal distress. Antenatal steroids and antibiotics administration are recommended by international guidelines. However, there is no recommendation regarding tocolysis administration in the setting of PPROM. In theory, reducing uterine contractility should delay delivery and reduce the risks of prematurity and neonatal adverse consequences. Likewise, a prolongation of gestation may allow administering a corticosteroids complete course that is associated with a two-fold reduction of morbidity and mortality. However, tocolysis may prolong fetal exposure to inflammation and be associated with higher risk of materno-fetal infection, potentially associated with neonatal death or long-term sequelae, including cerebral palsy.
The investigators implemented the TOCOPROM randomized clinical trial to assess whether short-term (48 hr) tocolysis reduces perinatal morti-morbidity in cases of PPROM at 22-33 weeks. However, both short- and long-term outcomes should be taken into account to define the optimal treatment strategy. There are currently no data allowing to evaluate the impact of a short course of nifedipine versus placebo on neurodevelopmental outcomes in school-aged children born after PPROM. Therefore, following-up children born to mothers enrolled in the TOCOPROM trial, through a new study, the TOCOKIDS cohort, is a unique and timely opportunity to advance scientific knowledge and adapt clinical practices in France and worldwide.
The assessment at 6 years of age will consist in:
Children born to women enrolled in the TOCOPROM trial reaching the age of 6 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exposure during pregnancy to Oral Nifedipine 20 mg LP (between 22 to 33 weeks of gestation): Loading dose at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg LP at T3, then 1 pill every 8 hours for 48 hours (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
Other: Self-administered parental questionnaire
Exposure during pregnancy to oral placebo of nifedipine (between 22 to 33 weeks of gestation) at T0, T0.5, T3, T11, T19, T27, T35 and T43
Other: A short psychological assessment performed online
A self-administered parental questionnaire, completed online or on paper, to assess different dimension of neurodevelopment
NEMI-3: an intelligence test administered by a psychologist measuring a fluid and crystallised intelligence. The test consists of 117 spoken and visual questions, for a total administration time of 45 min. Results are expressed in the form of standard indices (mean 100, standard deviation 15) that facilitate comparisons with the results obtained on other intelligence scales. Results will be classified as normal, mild delay (between 1 and \<2 standard deviation \[SD\] below the mean) or severe delay (≥2 SD).
Cerebral palsy at 6 years of age.
Cerebral palsy assessed using the Gross Motor Function Classification System (GMFCS), a five-level classification based on the child's current gross motor abilities, limitations in gross motor function, and need for assistive technology and wheeled mobility. Severe/moderate cerebral palsy (GMFCS≥2). Mild cerebral palsy (GMFCS-1).
Time frame: Up to 6 months after inclusion.
Developmental Coordination Disorder at 6 years of age.
Measured using the Developmental Coordination Disorder Questionnaire - European French (DCDQ-FE), a brief parent questionnaire (15 items) designed to screen for gross and fine motor skills and coordination disorders in children, aged 5 to 15 years. Total score=15-56: indication of a risk of DCD or suspected of a risk of DCD. Total score=57-75: probably no DCD.
Time frame: Up to 6 months after inclusion.
Language at 6 years of age
Language assessed using the verbal communication subscale (4 items) of the 5-15R scale, covering comprehension, expressive language skills and verbal communication, with an extra question on the impact of language and communication difficulties on daily activities. Mean (SD). Reference to cut-off scores in relation to the 90 and 98 percentiles (%).
Time frame: Up to 6 months after inclusion.
Behavior at 6 years of age.
Behavior assessed using the Strengths and Difficulties Questionnaire (SDQ), a brief behavioral screening questionnaire (25 items), designed to screen for symptoms of hyperactivity inattention, emotional, conduct, and peer problems among 2-17 year olds. Mean (SD). Abnormal: \>90th percentile. Mildly abnormal: 80-90 percentile.
Time frame: Up to 6 months after inclusion.
Executive functions at 6 years of age.
Executive functions measured using the Childhood Executive Functioning Inventory (CHEXI), a rating instrument (24 items) for parents that was developed for measuring executive functioning in children age 4-12. It includes four different subscales tapping working memory, planning, regulation and inhibition, combined into two global scales: working memory (working memory and planning subscales) and inhibition (inhibition and regulation subscales). Normative data are not yet available. Abnormality will be defined considering a cut-off or deviation compared to the mean score, depending on the literature.
Time frame: Up to 6 months after inclusion.
Vital status at 6 years of age.
Whether the child is alive or not at years of age.
Time frame: Up to 6 months after inclusion.
Neurodevelopmental impairment.
Moderate-to-severe impairment (severe/moderate cerebral palsy, and/or abnormal SDQ score, and/or NEMI-3 ≥2 SD below the mean, and/or blindness, and/or deafness), mild impairment (mildly abnormal scores or mild impairment) vs no neurodevelopmental impairment.
Time frame: Up to 6 months after inclusion.
Survival without any neurodevelopmental impairment at 6 years of age.
Survival without any neurodevelopmental impairment (as defined in the primary endpoint, and then including also cognitive impairment).
Time frame: Up to 6 months after inclusion.
Survival without moderate-to-severe neurodevelopmental impairment at 6 years of age.
Survival without moderate-to-severe neurodevelopmental impairment (i.e. severe/moderate cerebral palsy, and/or abnormal SDQ score, and/or NEMI-3 ≥2 SD below the mean, and/or blindness, and/or deafness).
Time frame: Up to 6 months after inclusion.
Growth at 6 years of age.
Height compulsory examination in the sixth year, reported in the health book.
Time frame: Up to 6 months after inclusion.
Growth at 6 years of age
Weight. Compulsory examination in the sixth year, reported in the health book
Time frame: Up to 6 months after inclusion
Health at 6 years of age.
Arterial pressure. Compulsory examination in the sixth year, reported in the health book.
Time frame: Up to 6 months after inclusion.
Health at 6 years of age
chronic diseases, compulsory examination in the sixth year, reported in the health book
Time frame: Up to 6 months after inclusion
Health at 6 years of age
oral health. Compulsory examination in the sixth year, reported in the health book
Time frame: Up to 6 months after inclusion
Vision at 6 years of age.
Visual acuity, any vision problem mentioned. Compulsory examination in the sixth year, reported in the health book.
Time frame: Up to 6 months after inclusion.
Hearing at 6 years of age.
Hearing test. Compulsory examination in the sixth year, reported in the health book.
Time frame: Up to 6 months after inclusion.
Development at 6 years of age.
Data reported in the health book during the compulsory examination in the sixth year.
Time frame: Up to 6 months after inclusion.
Language at 6 years of age.
Language test. Compulsory examination in the sixth year, reported in the health book.
Time frame: Up to 6 months after inclusion.
Behaviour at 6 years of age.
Data reported in the health book during the compulsory examination in the sixth year.
Time frame: Up to 6 months after inclusion.
Cognition at 6 years of age.
NEMI-3: an intelligence test administered by a psychologist measuring a fluid and crystallised intelligence. The test consists of 117 spoken and visual questions, for a total administration time of 45 min. Results are expressed in the form of standard indices (mean 100, standard deviation 15) that facilitate comparisons with the results obtained on other intelligence scales. Results will be classified as normal, mild delay (between 1 and \<2 standard deviation \[SD\] below the mean) or severe delay (≥2 SD).
Time frame: Up to 6 months after inclusion.
Feasibility of performing an online psychological evaluation.
Acceptability E-Scale (adapted - 3 items), participation and completion rates, technical difficulties.
Time frame: Up to 6 months after inclusion.
Parent-reported health and development.
Self-reported. Perceived health and development of the child, parental concerns about health and development, and professional diagnoses of health conditions (e.g., asthma, respiratory problems, etc.).
Time frame: Up to 6 months after inclusion.
Parent-reported Health-Related Quality of Life.
PedsQL Short Form - 15 items. All items will be added up and linearly transformed on a scale between 0 and 100, a higher score indicating a better HRQoL. Physical and psychosocial functioning will be further assessed using the corresponding subscales. Poor HRQoL, physical or psychosocial functioning will be defined using thresholds compatible with a severe health condition.
Time frame: Up to 6 months after inclusion.
Parent-reported school difficulties
Ad-hoc questions
Time frame: Up to 6 months after inclusion
Maternal self-perceived health
Minimum European Health Module - 1 item
Time frame: Up to 6 months after inclusion
Maternal mental health
PHQ-4 (anxiety and depression) - 4 items
Time frame: Up to 6 months after inclusion
Maternal well-being
WHO-5 Well-Being Index - 5 items
Time frame: Up to 6 months after inclusion
Maternal quality of life
WHOQOL bref FR - 1 item
Time frame: Up to 6 months after inclusion
Plan to share: No
Started Oct 2025 (actual). Primary completion is estimated for Sep 2033, 95 months after the start.
Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 95 months is above that.
Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →